BR112015010501A2 - composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada - Google Patents
composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizadaInfo
- Publication number
- BR112015010501A2 BR112015010501A2 BR112015010501A BR112015010501A BR112015010501A2 BR 112015010501 A2 BR112015010501 A2 BR 112015010501A2 BR 112015010501 A BR112015010501 A BR 112015010501A BR 112015010501 A BR112015010501 A BR 112015010501A BR 112015010501 A2 BR112015010501 A2 BR 112015010501A2
- Authority
- BR
- Brazil
- Prior art keywords
- nanoparticles
- freeze
- patient
- compound
- treating cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261725213P | 2012-11-12 | 2012-11-12 | |
US201361776951P | 2013-03-12 | 2013-03-12 | |
PCT/US2013/069550 WO2014075035A1 (en) | 2012-11-12 | 2013-11-12 | Bendamustine derivatives and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015010501A2 true BR112015010501A2 (pt) | 2017-07-11 |
Family
ID=49667594
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015010501A BR112015010501A2 (pt) | 2012-11-12 | 2013-11-12 | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada |
Country Status (17)
Country | Link |
---|---|
US (7) | US9452988B2 (pt) |
EP (1) | EP2917183A1 (pt) |
JP (1) | JP6262246B2 (pt) |
KR (1) | KR20150086308A (pt) |
AR (1) | AR093457A1 (pt) |
AU (1) | AU2013342015B2 (pt) |
BR (1) | BR112015010501A2 (pt) |
CA (1) | CA2890462A1 (pt) |
CL (1) | CL2015001246A1 (pt) |
EA (1) | EA029706B1 (pt) |
HK (2) | HK1215701A1 (pt) |
IL (1) | IL238662A (pt) |
MX (1) | MX2015005805A (pt) |
PH (1) | PH12015501024A1 (pt) |
SG (1) | SG11201503560TA (pt) |
TW (1) | TWI598341B (pt) |
WO (1) | WO2014075035A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX365251B (es) | 2010-05-20 | 2019-05-28 | Array Biopharma Inc | Compuestos macrocíclicos como inhibidores de trk cinasa. |
TWI598341B (zh) | 2012-11-12 | 2017-09-11 | 伊格尼塔公司 | 苯達莫司汀衍生物及其使用方法 |
WO2014164957A1 (en) * | 2013-03-12 | 2014-10-09 | Cephalon, Inc. | Nanoparticulate and macroparticulate formulations |
PL3322706T3 (pl) | 2015-07-16 | 2021-07-19 | Array Biopharma, Inc. | Podstawione związki pirazolo[1,5-a]pirydynowe jako inhibitory kinazy ret |
US11071789B2 (en) * | 2016-07-13 | 2021-07-27 | Cephalon, Inc. | Pharmaceutical prodrugs and methods of their preparation and use |
TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
TWI802635B (zh) | 2018-01-18 | 2023-05-21 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡咯并[2,3-d]嘧啶化合物 |
TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
US11524963B2 (en) | 2018-01-18 | 2022-12-13 | Array Biopharma Inc. | Substituted pyrazolo[3,4-d]pyrimidines as RET kinase inhibitors |
KR102653681B1 (ko) | 2018-07-31 | 2024-04-03 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의분무-건조된 분산물 및 제제 |
ES2922314T3 (es) | 2018-09-10 | 2022-09-13 | Array Biopharma Inc | Compuestos heterocíclicos condensados como inhibidores de cinasa RET |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681964A (en) * | 1990-10-23 | 1997-10-28 | University Of Kentucky Research Foundation | Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents |
US5834025A (en) | 1995-09-29 | 1998-11-10 | Nanosystems L.L.C. | Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions |
US7089218B1 (en) | 2004-01-06 | 2006-08-08 | Neuric Technologies, Llc | Method for inclusion of psychological temperament in an electronic emulation of the human brain |
US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
EP1343494A4 (en) | 2000-12-01 | 2005-08-03 | Enzon Inc | PROMOTERS TETRAPARTATES |
AU2003227147A1 (en) * | 2002-04-05 | 2003-10-27 | Universite De Montreal | Stealthy polymeric biodegradable nanospheres and uses thereof |
DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
US8436190B2 (en) | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
EP2301531B1 (en) | 2005-02-18 | 2018-06-06 | Abraxis BioScience, LLC | Combinations and modes of administration of therapeutic agents and combination therapy |
DE102005062440B4 (de) * | 2005-12-27 | 2011-02-24 | Lts Lohmann Therapie-Systeme Ag | Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen |
JP5537753B2 (ja) * | 2007-11-28 | 2014-07-02 | セレーター ファーマスーティカルズ、インク. | 改良されたタキサン送達システム |
AR072777A1 (es) | 2008-03-26 | 2010-09-22 | Cephalon Inc | Formas solidas de clorhidrato de bendamustina |
AU2009296734B2 (en) | 2008-09-25 | 2016-02-18 | Cephalon Llc | Liquid formulations of bendamustine |
US9149441B2 (en) * | 2008-09-29 | 2015-10-06 | The Corporation Of Mercer University | Nanospheres encapsulating bioactive material and method for formulation of nanospheres |
WO2010042568A1 (en) | 2008-10-08 | 2010-04-15 | Cephalon, Inc. | Processes for the preparation of bendamustine |
PT2367542E (pt) * | 2008-12-03 | 2014-03-10 | Astellas Deutschland Gmbh | Formas de dosagem oral de bendamustina |
MX2012013872A (es) | 2010-06-02 | 2013-04-03 | Astellas Deutschland Gmbh | Formas de dosificacion oral de bendamustina. |
TWI455722B (zh) | 2010-06-04 | 2014-10-11 | Pfizer Vaccines Llc | 用於預防或治療菸鹼成癮之共軛體 |
CN101966158A (zh) | 2010-09-28 | 2011-02-09 | 上海丽思化工科技有限公司 | 一种注射用盐酸苯达莫司汀冻干粉针剂及其制备方法 |
US20130217888A1 (en) | 2010-11-01 | 2013-08-22 | Shailpa Medicare Limited | Process for preparing bendamus tine hydrochloride monohydrate |
DE102010055499A1 (de) * | 2010-12-22 | 2011-06-16 | W.C. Heraeus Gmbh | Prozess zur Herstellung von Bendamustinalkylester, Bendarmustin sowie Derivaten davon |
US9427477B2 (en) | 2011-05-09 | 2016-08-30 | Mayo Foundation For Medical Education And Research | Cancer treatments |
US9308276B2 (en) | 2011-05-17 | 2016-04-12 | University Of South Alabama | Combination therapy for treatment of cancer |
EP2760842B1 (en) | 2011-09-26 | 2016-11-16 | Fresenius Kabi Oncology Ltd | An improved process for the preparation of bendamustine hydrochloride |
DK2656843T3 (en) | 2012-04-26 | 2015-04-20 | Helmut Schickaneder | Esters of bendamustine and related compounds, and medical use thereof |
KR101955065B1 (ko) | 2012-06-19 | 2019-03-06 | 헬무트 쉬카네더 | 벤다무스틴 유도체 및 관련 화합물, 및 이의 암 치료 의약 용도 |
WO2014025890A1 (en) | 2012-08-10 | 2014-02-13 | University Of North Texas Health Science Center | Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids |
TWI598341B (zh) * | 2012-11-12 | 2017-09-11 | 伊格尼塔公司 | 苯達莫司汀衍生物及其使用方法 |
-
2013
- 2013-11-12 TW TW102140964A patent/TWI598341B/zh not_active IP Right Cessation
- 2013-11-12 JP JP2015541995A patent/JP6262246B2/ja not_active Expired - Fee Related
- 2013-11-12 CA CA2890462A patent/CA2890462A1/en not_active Abandoned
- 2013-11-12 WO PCT/US2013/069550 patent/WO2014075035A1/en active Application Filing
- 2013-11-12 KR KR1020157015682A patent/KR20150086308A/ko not_active Application Discontinuation
- 2013-11-12 MX MX2015005805A patent/MX2015005805A/es unknown
- 2013-11-12 AR ARP130104160A patent/AR093457A1/es unknown
- 2013-11-12 BR BR112015010501A patent/BR112015010501A2/pt not_active IP Right Cessation
- 2013-11-12 AU AU2013342015A patent/AU2013342015B2/en not_active Ceased
- 2013-11-12 SG SG11201503560TA patent/SG11201503560TA/en unknown
- 2013-11-12 EP EP13795940.9A patent/EP2917183A1/en not_active Withdrawn
- 2013-11-12 EA EA201590925A patent/EA029706B1/ru not_active IP Right Cessation
- 2013-11-12 US US14/442,088 patent/US9452988B2/en not_active Expired - Fee Related
-
2015
- 2015-04-29 US US14/699,965 patent/US9150517B2/en not_active Expired - Fee Related
- 2015-05-06 IL IL238662A patent/IL238662A/en not_active IP Right Cessation
- 2015-05-07 PH PH12015501024A patent/PH12015501024A1/en unknown
- 2015-05-08 CL CL2015001246A patent/CL2015001246A1/es unknown
- 2015-05-13 US US14/711,747 patent/US9149464B2/en not_active Expired - Fee Related
- 2015-09-28 US US14/868,278 patent/US20160016912A1/en not_active Abandoned
-
2016
- 2016-01-06 HK HK16100090.1A patent/HK1215701A1/zh unknown
- 2016-01-27 HK HK16100891.2A patent/HK1212977A1/zh unknown
- 2016-06-16 US US15/184,968 patent/US9630926B2/en not_active Expired - Fee Related
-
2017
- 2017-03-10 US US15/456,439 patent/US9913827B2/en not_active Expired - Fee Related
-
2018
- 2018-01-24 US US15/879,130 patent/US20180147186A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015010501A2 (pt) | composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada | |
BR112015007061A2 (pt) | composto, composição farmacêutica e método para tratar uma condição ou distúrbio dependente de apkc em um paciente | |
HK1215378A1 (zh) | 藥物組合物、治療方法及其用途 | |
BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
BR112013033078A2 (pt) | partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
BR112012018947A2 (pt) | composição farmacêutica para tratamento e\ou prevenção do cancêr | |
PL2818483T3 (pl) | Kompozycja lecznicza do leczenia i/lub zapobiegania nowotworowi | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
BR112015004489A2 (pt) | composto, composição farmacêutica, e, métodos para tratar um distúrbio proliferativo e para sintetizar um composto | |
PL2672966T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
BR112012018943A8 (pt) | medicamento e método para o tratamento e/ou prevenção de um câncer | |
BR112014023937A2 (pt) | composição farmacêutica, agente farmacêutico de combinação e método de tratamento | |
BR112012018951A2 (pt) | composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo | |
BR112014032105A2 (pt) | método para o tratamento de câncer | |
PL2729151T3 (pl) | Kompozycja farmaceutyczna, sposoby leczenia i jej zastosowania | |
BR112014031896A2 (pt) | composto, composição farmacêutica, e, método para o tratamento de um distúrbio | |
BR112013018679A2 (pt) | agente para o tratamento da alopecia | |
SG11201504791VA (en) | Pharmaceutical composition for treating headache, and preparation method thereof | |
BR112014031899A8 (pt) | composto, composição farmacêutica, e, método para tratamento de um distúrbio | |
EP2709614A4 (en) | PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF CANCER | |
BR112014031512A2 (pt) | composição cosmética e método para o tratamento cosmético. | |
BR112014015753A8 (pt) | derivado do polímero da quitosana, composição farmacêutica, método para o tratamento, utilização e presente invenção | |
EP2823825A4 (en) | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2540 DE 10-09-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |